Ceritinib for Untreated Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal

Overview of attention for article published in PharmacoEconomics, October 2018

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age

Mentioned by

twitter: 4 X users

facebook: 1 Facebook page

Citations

dimensions_citation: 6 Dimensions

Readers on

mendeley: 57 Mendeley

Summary X Facebook Dimensions citations

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 7,169 followers.

RT @crd_york: New paper from our Evidence Review Group - Ceritinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cel…

11 Oct 2018

Reply Repost Favourite

New paper from our Evidence Review Group - Ceritinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung: an Evidence Review Group evaluation of a NICE Single Technology Appraisal https://t.co/mLLs9OwLW8

11 Oct 2018

Reply Repost Favourite

Ceritinib for Untreated Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal. #lymphoma #lymsm https://t.co/npx2jfZs0c

10 Oct 2018

Reply Repost Favourite

#HealthEconJA Ceritinib for Untreated Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal https://t.co/SYKW6xqG8k

08 Oct 2018

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.